Get the Stockscreener App
1.18
4.07%
-0.05
After Hours:
1.20
0.02
+1.69%
Neurosense Therapeutics Ltd stock is traded at $1.18, with a volume of 121.02K.
It is down -4.07% in the last 24 hours and up +10.28% over the past month.
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases, these diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release, or ER, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.
See More
Previous Close:
$1.23
Open:
$1.25
24h Volume:
121.02K
Relative Volume:
0.52
Market Cap:
$23.47M
Revenue:
-
Net Income/Loss:
$-13.76M
P/E Ratio:
-0.9147
EPS:
-1.29
Net Cash Flow:
-
1W Performance:
-10.61%
1M Performance:
+10.28%
6M Performance:
-2.48%
1Y Performance:
+122.22%
1-Day Range:
$1.1399
$1.265
1-Week Range:
$1.1399
$1.35
52-Week Range:
$0.4702
$2.33
Neurosense Therapeutics Ltd Stock (NRSN) Company Profile
Name
Neurosense Therapeutics Ltd
Sector
Industry
Phone
-
Address
-
Compare NRSN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| NRSN | 1.18 | 23.47M | 0 | -13.76M | 0 | -1.29 |
| VRTX | 467.01 | 119.87B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 762.00 | 83.27B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 567.90 | 33.96B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 232.27 | 30.18B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 101.87 | 24.42B | 3.30B | -501.07M | 1.03B | 11.54 |
Neurosense Therapeutics Ltd Stock (NRSN) Latest News
NeuroSense to Participate in Upcoming ALS Conferences: PACTALS i - GuruFocus.com
NeuroSense Therapeutics Secures Continued Nasdaq Listing - TipRanks
Amyotrophic Lateral Sclerosis Treatment Market to Grow by USD 663.7 Million from 2024-2028, as Rising Incidence Drives Demand with AI Redefining Market LandscapeTechnavio - The Malaysian Reserve
4 Biotech Stocks With AI, Machine Learning Prowess - Investing.com
NeuroSense Moves Toward Early Commercialization Of ALS Treatment In Canada, Eyeing $100M+ Market - MSN
Neurosense Therapeutics Secures $30 Million Equity Deal - TipRanks
NeuroSense Therapeutics Announces Private Placement with Senior - GuruFocus.com
NeuroSense Completes Key ALS Trial Phase - TipRanks
NeuroSense Therapeutics : INFORMATION CONTAINED IN THIS REPORT ON FORM 6 K Form 6 K - Marketscreener.com
NeuroSense schedules FDA meeting for ALS drug trial - Investing.com India
NeuroSense Therapeutics Advances ALS Drug Development Plans - TipRanks
NeuroSense schedules FDA meeting for ALS drug trial By Investing.com - Investing.com Australia
NeuroSense Therapeutics Ltd. Secures Key FDA Meeting to Advance its Phase 3 ALS Trial and NDA Submission - Marketscreener.com
NeuroSense Secures Key FDA Meeting to Advance its Phase 3 ALS Trial and NDA Submission - Nasdaq
EXCLUSIVE: Nano-Cap NeuroSense Schedules FDA Meeting To Advance Lead Program And Marketing Application Submission - Benzinga
NRSNNeuroSense Therapeutics Ltd. Ordinary Shares Latest Stock News & Market Updates - StockTitan
NeuroSense’s PrimeC Shows Potential in ALS Treatment - TipRanks
NeuroSense Therapeutics : New Analysis Shows PrimeC Significantly Improves Key miRNAs in ALS Patients Form 6 K - Marketscreener.com
Neurosense Therapeutics Ltd. Announces Transformative Findings from Its Paradigm Clinical Trial of PrimeC - Marketscreener.com
NeuroSense Advances Plans For Early Commercialization Of Potentially Groundbreaking ALS Treatment In Canada, Targeting A $100M+ Market - Nasdaq
NeuroSense Advances Plans For Early Commercialization Of Potentially Groundbreaking ALS Treatment In Canada, Targeting A $100M+ Market | StreetInsider.com - Financial Content
NeuroSense seeks early Canada approval for ALS drug By Investing.com - Investing.com Nigeria
NeuroSense Advances Plans for Early Commercialization of Groundbreaking ALS Treatment in Canada, Provides Further Updates - Citizentribune
NeuroSense seeks early Canada approval for ALS drug - Investing.com
NeuroSense Targets Key ALS Drug Market in Canada - TipRanks
NeuroSense Targets Early ALS Drug Approval in Canada - TipRanks
NeuroSense Therapeutics Plans to File for Early Commercialization of ALS Treatment in Canada - PR Newswire
NeuroSense Therapeutics Announces Acceptance of Two PrimeC Abstracts at the 2024 NEALS Annual Meeting - PR Newswire
NeuroSense Therapeutics Ltd. Expands its Phase 2b ALS PARADIGM Trial to Canada and Withdraws Protocol from U.S. IND to Align its Clinical Strategy with the FDA for a Potential Pivotal Phase 3 Study - Marketscreener.com
XTX Topco Ltd Invests $37,000 in NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) - Defense World
NeuroSense Therapeutics Reports Mid-Year Financials - TipRanks
In the Green: NeuroSense Therapeutics Ltd (NRSN) Closes at 1.25, Up/Down -3.50 from Previous Day - The Dwinnex
NeuroSense extends PrimeC patent protection to 2042 By Investing.com - Investing.com Australia
NeuroSense back in line with Nasdaq bid price rule By Investing.com - Investing.com Australia
NeuroSense back in line with Nasdaq bid price rule - Investing.com
NeuroSense extends PrimeC patent protection to 2042 - Investing.com
NeuroSense Back on Track with NASDAQ Compliance - TipRanks
NeuroSense Therapeutics Granted Key U.S. Patent for Novel PrimeC Formulation, its Lead Asset for ALS and Alzheimer's - PR Newswire
NeuroSense Regains Compliance with NASDAQ Minimum Bid Price Rule - PR Newswire
Naspers (OTCMKTS:NPSNY) Share Price Passes Above 50-Day Moving Average of $39.49 - Defense World
SenesTech stock hits 52-week low at $2.4 amid sharp decline - Investing.com
This £300 health scan has a 10k waitlist — I tried it and found out why it's so worth it - Evening Standard
Sachin Tendulkar stock jumps 8% after it gets buy call for an upside of 20% - Trade Brains
Neuralink Blindsight receives FDA Breakthrough Device Designation for visually impaired patients - Shacknews
TSX Composite Index (TXCX) QuotePress Release - The Globe and Mail
Quest Partners LLC Sells 3,065 Shares of Napco Security Technologies, Inc. (NASDAQ:NSSC) - Defense World
Surgery-free Neuralink rival enables thought-controlled smart home - New Atlas
Mind Medicine (MindMed) (NASDAQ:MNMD) Given New $14.00 Price Target at Canaccord Genuity Group - Defense World
NeuroSense Embarks on HIPAA Compliance Journey - TipRanks
Quest Partners LLC Has $298,000 Position in Northern Trust Co. (NASDAQ:NTRS) - Defense World
NeuroSense Therapeutics Ltd: -52.36% Growth from 52-Week Low, Yet Analysts Divided - The InvestChronicle
Neurosense Therapeutics Ltd Stock (NRSN) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.66%
1.11%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):